---
title: Pfizer Inc. (PFE)
layout: default
nav_order: 79
---

# Pfizer Inc.
{: .fs-9 }

{: .label .label-purple }

Moat: 3/5

{: .label .label-blue }

Management: 3/5

{: .label .label-green }

Catalyst: 2/5

{: .label .label-yellow }

Pessimistic value: $170 B

Pfizer is a large pharmaceutical company with a history of developing and marketing successful drugs. While the company has a diverse portfolio of products, its primary focus is on prescription drugs.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=PFE+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/PFE/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning } 
>The moat rating, management rating, catalyst score, and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.


**Moat:**

Pfizer's moat rating of 3 / 5 reflects its established brand name, large size, and substantial R&D spending. This grants some competitive advantages in pricing power, economies of scale, and regulatory approvals, etc. However, the pharmaceutical industry is characterized by significant competition, patent expirations, and the rise of generics, limiting its moat rating.

> As Pat Dorsey writes in *The Little Book That Builds Wealth*, "Patents are wonderful to have, but patent lawyers are not poor... Legal challenges are the biggest risk to a patent moat." This limits the durability of patent-based moats in the pharmaceutical industry. 


**Management:**

Pfizer's management rating of 3 / 5 reflects a mixed assessment. On the positive side, the company has a history of consistent profitability and dividend payments, which aligns the interest of long-term shareholders with the performance of the company. This is good for outside shareholders.

> As Warren Buffett writes in "A Principled Approach to Executive Pay," "The best form of corporate governance... isn't necessarily the most 'modern' in appearance... Rather it's the consistent application of sound business judgment." Pfizer's management has generally demonstrated this, keeping their focus on steady, long-term returns.

However, Pfizer's management team's heavy reliance on acquisitions for growth, as seen with the Seagen acquisition, raises concerns about capital allocation decisions.  

> As Warren Buffet writes in the *Essays of Warren Buffett*: "Many managerial princesses remain secure in their confident (about the future) knowledge that in their kissesâ€”even rarely confident backyards are knee-deep in unresponsive toads.  Two major characteristics (even without product demand) that is ability to (1) increase prices rather easily and (2) on an incremental (or additional) investment of one dollar by management."  The Seagen acquisition raises questions about overpaying for growth and the potential dilution of shareholder value.  


**Catalyst:**

Pfizer's catalyst rating of 2 / 5 is moderate. The company's pipeline shows promise, and its continued focus on developing new drugs and therapies could provide a boost to revenues and earnings. However, there is always the risk of clinical trial failures and regulatory hurdles in the pharmaceutical industry.

>From the Q2 2023 earnings call: "...excited about the strength of our pipeline with multiple potential new product launches... and we are increasingly encouraged by earlier stage assets across our entire pipeline... with several now advancing to later stages of clinical development..."

Recent concerns about declining COVID-19 vaccine revenue may create downward pressure on the stock price, but the company's diverse portfolio and pipeline could mitigate this risk. Additionally, cost-cutting measures and increased operational efficiencies could improve margins and boost profitability. 


**Business:**

Pfizer operates in a highly competitive and regulated industry. It faces competition from both brand-name and generic drug manufacturers. 

> As Michael Porter writes in *Competitive Advantage*, "In commodity markets, companies are typically price takers, meaning they must sell at the market price."  While Pfizer tries to differentiate with innovative drugs and quality, pricing pressure remains a constant threat.


Pfizer's revenue streams are largely linked to its branded prescription drugs.  Recent revenue growth has been driven primarily by its COVID-19 vaccine and Paxlovid, but sales are expected to decline as the pandemic wanes.  The company's focus on developing new drugs and expanding into new geographic markets could help offset this decline.

> From Pfizer's Q4 2022 earnings call: "We expect to see continued strong growth in our core business even without the contribution from COVID-19 and Paxlovid."

Pfizer's margins are relatively high for the industry, but they could be squeezed as competition intensifies and costs rise. The company's focus on cost-cutting measures and increased efficiencies could help mitigate this risk.

**Financials:**

Pfizer has a history of consistent profitability and strong cash flows. However, the company's heavy reliance on debt financing raises concerns about its financial health.  Its debt burden could limit its flexibility to make acquisitions and reinvest in its business, particularly in the down part of the business cycle, making it susceptible to adverse shocks.

> As Koller, Goedhart, and Wessels write in *Valuation*, "Leverage is a double-edged sword... Debt increases the company's expected return on equity only when the shareholders expect the rate of return from the operations of the business to be greater than the after-tax cost of debt."


**Valuation:**

> **Valuation Assumptions and Calculations:**

To estimate Pfizer's intrinsic value, I employed a discounted cash flow (DCF) model with pessimistic assumptions.  

1. **Revenues:**  Assumed revenue growth of 2% annually for the next 5 years, declining to 1% in perpetuity. This reflects the expected decline in COVID-related revenues and increased competition.

2. **Margins:** Assumed a gradual decline in operating margins from 35% to 25% over the next 10 years, reflecting pricing pressure and rising costs.

3. **Reinvestment Rate:** Assumed a reinvestment rate of 40%, reflecting Pfizer's continued investments in R&D and acquisitions.

4. **Cost of Capital:** Estimated a cost of capital of 7%, reflecting the risk of investing in a mature, competitive industry. Given Pfizer's history of acquisitions and the increased risk related to these acquisitions, we have assumed a higher cost of capital than may otherwise be applicable

5. **Terminal Value:** Calculated using the perpetuity growth method, assuming a terminal growth rate of 1% and a cost of capital of 7%.


> **Results:**

Based on these pessimistic assumptions, Pfizer's intrinsic value is estimated at approximately **$170 billion**, roughly in line with its current market value (as of the time of this analysis). This suggests the stock is fairly valued, with little margin of safety.  This valuation is a probability-weighted valuation considering multiple scenarios and including a scenario where Pfizer's COVID-19 products cease to sell after the next 5 years.


**Conclusion:**

Pfizer is a large, established pharmaceutical company with a moderate moat.  Its management has a mixed record, and its financials are burdened by debt, especially given its history of making acquisitions.  The stock appears fairly valued based on pessimistic assumptions. Given the limited upside potential and high reinvestment needs, Pfizer might not be a compelling investment for a value-focused investor at its current price.


**Disclaimer:** This is not investment advice. Do your own research before making any investment decisions.